Clinical Intelligence

Omeros begins enrollment in second phase III OMS302 trial

Wednesday, April 11, 2012 03:52 PM

Omeros, a Seattle-based biopharmaceutical company, has commenced enrollment in a second phase III clinical trial evaluating OMS302 in intraocular lens replacement (ILR) surgery.

More... »

QRxPharma concludes phase I studies for MoxDuo CR

Wednesday, April 11, 2012 03:28 PM

Australia-based QRxPharma has completed two phase I studies in healthy volunteers for MoxDuo CR, a controlled-release Dual-Opioid utilizing a 3:2 ratio of morphine and oxycodone.

More... »

BIND Bioscience releases promising anti-tumor results

Wednesday, April 11, 2012 02:52 PM

BIND Biosciences, a clinical-stage biopharmaceutical company, has releases promising data from an ongoing phase I study of BIND-014, the company’s lead drug candidate within a new class of targeted therapeutics, Accurins, that are programmed to concentrate at tumors.

More... »

Syndax initiates phase I/II study in metastatic breast cancer

Monday, April 9, 2012 04:42 PM

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company based in Waltham, Mass., has initiated a phase I/II study combining its lead product entinostat with lapatinib ditosylate (Tykerb) in patients with locally recurrent or distant relapsed metastatic breast cancer previously treated with trastuzumab (Herceptin).

More... »

CureFAKtor drug inhibits pancreatic tumor growth

Friday, April 6, 2012 04:14 PM

CureFAKtor Pharmaceuticals, a privately-held biopharmaceutical company, has reported data demonstrating analogs of novel focal adhesion kinase (FAK) inhibitor CFAK-C4 disrupted FAK-vascular endothelial growth factor receptor 3 (FAK-VEGFR3) interaction and inhibited pancreatic tumor growth.

Data showed that oral small molecule FAK inhibitor C4 analogs disrupt FAK-VEGFR3 interaction and dramatically inhibit pancreatic tumor growth at low concentrations as single agents, as well as in combination with gemcitabine, demonstrating synergistic effect. In vivo, 30-day treatment with low doses of the four analogs led to massive reduction in tumor growth when treated as single agents (60%) and in combination with gemcitabine (80%) (P<0.05). The C4 analogs displayed enhanced potency, minimum toxicity and high specificity for the target site.

A previous CureFAKtor study pinpointed the site of interaction of VEGFR-3 and FAK to create the small molecule drug capable of disrupting signaling and causing death of many types of cancer cells.

CureFAKtor is planning a phase I clinical study of CFAK-C4 in combination with gemcitabine chemotherapy in 2012, which received Orphan Drug Designation by the FDA.

More... »

UCB, Amgen begin phase III postmenopausal osteoporosis program

Friday, April 6, 2012 03:47 PM

UCB, a global biopharmaceutical based in Brussels, Belgium, and biotech Amgen have initiated their sclerostin antibody (CDP7851/AMG785) phase III clinical trial program for the treatment of postmenopausal osteoporosis.

More... »

Novartis phase III COPD studies meet primary endpoints

Friday, April 6, 2012 03:08 PM

The first three Novartis Pharmaceuticals QVA149 phase III studies in the treatment of chronic obstructive pulmonary disease (COPD) all met their primary endpoints.

More... »

Abbott touts promising results in phase II Hep C trial

Thursday, April 5, 2012 08:00 AM

Abbott has released promising data from two different interferon-free phase II studies for hepatitis C (HCV), suggesting that a 12-week regimen of two Abbott medicines, and no peginterferon, can achieve high cure rates for treatment-naïve, genotype 1 patients.

More... »

Synta releases data on ganetespib across range of malignancies

Wednesday, April 4, 2012 09:00 AM

Lexington, Mass.-based Synta Pharmaceuticals has released results on the use of ganetespib, the most advanced heat shock protein 90 (Hsp90) inhibitor in clinical development, in melanoma and colorectal cancer.

More... »

The CenterWatch Monthly, April 2012

Sunday, April 1, 2012 06:30 AM

Global sites see growth in trials, revenue, staffing

More... »